HC Wainwright Cuts Zura Bio (NASDAQ:ZURA) Price Target to $3.00

Zura Bio (NASDAQ:ZURA) had its price target cut by HC Wainwright from $5.00 to $3.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other research firms have also recently commented on ZURA. Oppenheimer restated an “outperform” rating and set a $19.00 price target (down from $20.00) on shares of Zura Bio in a report on Wednesday, March 26th. Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Wednesday, December 11th. Chardan Capital cut their price target on Zura Bio from $12.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, March 26th. Finally, Guggenheim reissued a “buy” rating and issued a $15.00 price target on shares of Zura Bio in a research note on Wednesday, March 26th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Zura Bio presently has an average rating of “Buy” and a consensus target price of $14.67.

Zura Bio Trading Down 7.3 %

Shares of ZURA stock opened at $1.09 on Thursday. The company has a market capitalization of $70.84 million, a price-to-earnings ratio of -2.05 and a beta of 0.08. Zura Bio has a 1-year low of $0.98 and a 1-year high of $6.35. The stock’s fifty day simple moving average is $1.41 and its 200-day simple moving average is $2.67.

Zura Bio (NASDAQ:ZURA) last issued its earnings results on Tuesday, March 25th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.09. The business had revenue of $0.00 million during the quarter. On average, sell-side analysts predict that Zura Bio will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Zura Bio

Large investors have recently added to or reduced their stakes in the stock. Charles Schwab Investment Management Inc. lifted its stake in shares of Zura Bio by 51.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 291,807 shares of the company’s stock worth $1,185,000 after buying an additional 98,972 shares during the last quarter. The Manufacturers Life Insurance Company bought a new position in Zura Bio in the 3rd quarter worth $71,000. MetLife Investment Management LLC acquired a new position in Zura Bio during the 3rd quarter worth $111,000. State Street Corp boosted its holdings in Zura Bio by 47.5% during the third quarter. State Street Corp now owns 395,059 shares of the company’s stock valued at $1,604,000 after acquiring an additional 127,300 shares during the period. Finally, Sphera Funds Management LTD. acquired a new stake in shares of Zura Bio in the third quarter valued at about $2,999,000. Institutional investors own 61.14% of the company’s stock.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.